Total Payments
$13,707
2024 Payments
$4,202
Companies
72
Transactions
685
Medicare Patients
8,660
Medicare Billing
$1.4M
Payment Breakdown by Category
Food & Beverage$12,976 (94.7%)
Education$730.92 (5.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,976 | 677 | 94.7% |
| Education | $730.92 | 8 | 5.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,085 | 54 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,050 | 59 | $0 (2024) |
| Celgene Corporation | $819.81 | 43 | $0 (2024) |
| Astellas Pharma US Inc | $762.87 | 28 | $0 (2024) |
| PFIZER INC. | $657.67 | 38 | $0 (2024) |
| Merck Sharp & Dohme LLC | $643.53 | 34 | $0 (2024) |
| Janssen Biotech, Inc. | $636.53 | 29 | $0 (2024) |
| Daiichi Sankyo Inc. | $552.11 | 22 | $0 (2024) |
| Incyte Corporation | $482.00 | 26 | $0 (2024) |
| Seagen Inc. | $449.83 | 22 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,202 | 189 | AstraZeneca Pharmaceuticals LP ($451.61) |
| 2023 | $3,909 | 198 | Novartis Pharmaceuticals Corporation ($413.17) |
| 2022 | $2,929 | 156 | Novartis Pharmaceuticals Corporation ($264.68) |
| 2021 | $2,304 | 121 | E.R. Squibb & Sons, L.L.C. ($179.75) |
| 2020 | $299.39 | 17 | AstraZeneca Pharmaceuticals LP ($41.22) |
| 2019 | $45.31 | 3 | GlaxoSmithKline, LLC. ($45.31) |
| 2017 | $18.20 | 1 | GlaxoSmithKline, LLC. ($18.20) |
All Payment Transactions
685 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/13/2024 | Menarini Silicon Biosystems, Inc. | Cellsearch (Device) | Food and Beverage | Cash or cash equivalent | $20.21 | General |
| Category: Diagnostics | ||||||
| 12/12/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $24.34 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Oncology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.93 | General |
| Category: Oncology | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $20.47 | General |
| 12/10/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $24.61 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 12/05/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $27.95 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.57 | General |
| 12/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $9.60 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $20.29 | General |
| Category: Oncology | ||||||
| 12/02/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.91 | General |
| Category: Hematology | ||||||
| 11/20/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $21.17 | General |
| Category: Hematology | ||||||
| 11/19/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $18.79 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $9.70 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $17.54 | General |
| Category: Hematology/Oncology | ||||||
| 11/14/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $33.61 | General |
| Category: HEMATOLOGY | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: Immunology | ||||||
| 11/12/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 39 | 2,361 | 137,088 | $3.0M | $786,169 |
| 2022 | 48 | 2,601 | 43,187 | $954,142 | $243,319 |
| 2021 | 53 | 2,785 | 38,006 | $1.1M | $333,837 |
| 2020 | 28 | 913 | 9,665 | $193,555 | $54,753 |
Total Patients
8,660
Total Services
227,946
Medicare Billing
$1.4M
Procedure Codes
168
All Medicare Procedures & Services
168 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 12 | 10,200 | $1.4M | $441,420 | 31.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 273 | 828 | $280,692 | $77,003 | 27.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 21 | 3,900 | $198,900 | $71,782 | 36.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 56 | 267 | $100,926 | $25,876 | 25.6% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 20 | 4,040 | $92,920 | $23,394 | 25.2% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 37 | 46,410 | $185,640 | $18,270 | 9.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 101 | 341 | $64,449 | $15,985 | 24.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 116 | 244 | $48,068 | $15,274 | 31.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 89 | 90 | $50,040 | $12,349 | 24.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 351 | 1,318 | $11,862 | $11,071 | 93.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 85 | 85 | $38,505 | $10,502 | 27.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 348 | 1,379 | $39,991 | $10,482 | 26.2% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 18 | 7,410 | $37,050 | $10,178 | 27.5% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 45 | 42,100 | $210,500 | $6,711 | 3.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 117 | 545 | $37,605 | $5,711 | 15.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 76 | 424 | $25,864 | $4,995 | 19.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 50 | 168 | $14,112 | $3,681 | 26.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 44 | 50 | $11,950 | $3,456 | 28.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 15 | 57 | $10,146 | $2,783 | 27.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 14 | 16 | $7,584 | $2,128 | 28.1% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 11 | 43 | $7,310 | $1,809 | 24.7% |
| Q5101 | Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 2023 | 11 | 12,780 | $25,560 | $1,801 | 7.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 22 | 83 | $6,557 | $1,767 | 27.0% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 39 | 101 | $5,656 | $1,582 | 28.0% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 27 | 61 | $3,599 | $1,042 | 29.0% |
About Dr. Swati Pathak, MD
Dr. Swati Pathak, MD is a Hematology healthcare provider based in Davenport, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/06/2008. The National Provider Identifier (NPI) number assigned to this provider is 1407012602.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Swati Pathak, MD has received a total of $13,707 in payments from pharmaceutical and medical device companies, with $4,202 received in 2024. These payments were reported across 685 transactions from 72 companies. The most common payment nature is "Food and Beverage" ($12,976).
As a Medicare-enrolled provider, Pathak has provided services to 8,660 Medicare beneficiaries, totaling 227,946 services with total Medicare billing of $1.4M. Data is available for 4 years (2020–2023), covering 168 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Internal Medicine, Hematology & Oncology
- Location Davenport, FL
- Active Since 08/06/2008
- Last Updated 06/15/2020
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1407012602
Products in Payments
- KEYTRUDA (Biological) $595.94
- Enhertu (Drug) $447.80
- REBLOZYL (Biological) $392.30
- DARZALEX (Biological) $360.23
- ZEPZELCA (Drug) $333.56
- OPDIVO (Biological) $330.09
- KISQALI (Drug) $329.18
- JAKAFI (Drug) $321.43
- Doptelet (Drug) $287.83
- LYNPARZA (Drug) $253.91
- IMFINZI (Biological) $243.38
- MYRISK (Device) $239.88
- MONJUVI (Drug) $234.03
- Lenvima (Drug) $233.60
- XTANDI (Drug) $232.22
- Nubeqa (Drug) $226.65
- COSELA (Drug) $225.75
- LIBTAYO (Biological) $222.62
- IMBRUVICA (Drug) $215.38
- Pomalyst (Drug) $215.16
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.